December 12, 2008
Gilead Sciences Files Patent Infringement Lawsuit Against Teva Pharmaceuticals

December 3, 2008
Data Demonstrating Significant Efficacy of Viread(R) in Treating Chronic Hepatitis B Published in New England Journal of Medicine

November 25, 2008
Gilead Sciences to Present at Two Upcoming Investor Conferences

November 14, 2008
Gilead Sciences Announces Notification of ANDA Filing for Truvada

November 5, 2008
Gilead Sciences to Present at Three Upcoming Investor Conferences

November 1, 2008
Gilead Announces Two-Year Data from Pivotal Phase III Studies Evaluating Viread(R) for Chronic Hepatitis B

October 30, 2008
Gilead Sciences to Present at the Oppenheimer 19th Annual Healthcare Conference on Tuesday, November 4

October 28, 2008
Gilead Announces Two-Year Clinical Data for Letairis(R) (ambrisentan) for the Treatment of Pulmonary Arterial Hypertension (WHO Group 1)

October 23, 2008
Gilead Signs Agreement with EFI to Acquire Building and Associated Land Bordering Gilead's Foster City Campus

October 16, 2008
Gilead Sciences Announces Third Quarter 2008 Financial Results

October 9, 2008
Gilead Sciences to Release Third Quarter 2008 Financial Results on Thursday, October 16, 2008

September 16, 2008
Gilead Receives Complete Response Letter from U.S. Food and Drug Administration for Aztreonam Lysine for Inhalation, an Investigational Treatment for Cystic Fibrosis

September 11, 2008
Seigo Izumo, MD Joins Gilead as Senior Vice President, Cardiovascular Therapeutics

September 10, 2008
Gilead Sciences to Present at Two Upcoming Investor Conferences

August 27, 2008
Gilead Sciences to Present at the Thomas Weisel Partners Healthcare Conference on Wednesday, September 3

August 11, 2008
U.S. Food and Drug Administration Approves Viread(R) for Chronic Hepatitis B in Adults

August 1, 2008
Gilead Sciences and Merck & Co., Inc. Enter Into an Agreement to Register and Distribute HIV Medication Atripla(R) (Efavirenz 600 mg/ Emtricitabine 200 mg/ Tenofovir Disoproxil Fumarate 300 mg) in Twelve Countries

July 31, 2008
Richard J. Whitley, MD Joins Gilead Sciences' Board of Directors

July 22, 2008
Gilead Initiates Phase III Clinical Trial of Elvitegravir, an Investigational Integrase Inhibitor for HIV

July 17, 2008
Gilead Sciences Announces Second Quarter 2008 Financial Results

July 8, 2008
Gilead Sciences to Release Second Quarter 2008 Financial Results on Thursday, July 17, 2008

June 13, 2008
Gilead Announces Interim 12-Month Phase III Study Results for Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis

June 4, 2008
Gilead Sciences to Present at the 29th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 11

June 2, 2008
U.S. Patent Office Confirms Second of Four Viread(R) Patents

May 29, 2008
Gilead and Navitas Announce Agreement for Cicletanine for the Treatment of Pulmonary Arterial Hypertension

May 29, 2008
Data from Pivotal Phase III Studies of Gilead's Letairis(R) (ambrisentan) for Pulmonary Arterial Hypertension (WHO Group 1) in Patients with WHO Functional Class II or III Symptoms Published in Circulation

May 22, 2008
Gilead Sciences' Chairman and Chief Executive Officer Establishes Rule 10b5-1 Stock Trading Plan

May 20, 2008
U.S. Patent Office Confirms First of Four Viread(R) Patents

May 20, 2008
Gilead Announces New Letairis(R) (Ambrisentan) Data for the Treatment of Patients With Pulmonary Arterial Hypertension (WHO Group 1) With WHO Functional Class II or III Symptoms

May 14, 2008
Gilead Sciences to Present at the 2008 Citi Investment Research Global Healthcare Conference on Wednesday, May 21

May 13, 2008
Gilead Sciences' Board Member Establishes Rule 10b5-1 Stock Trading Plan

May 9, 2008
Gilead Sciences to Present at the Bank of America 2008 Healthcare Conference on Tuesday, May 13

May 7, 2008
Gilead Appoints John C. Martin as Chairman of Board of Directors; Names John F. Milligan President

May 1, 2008
Gilead Initiates Letairis(R) (ambrisentan) Phase IV Program

April 25, 2008
European Commission Approves Viread(R) for Chronic Hepatitis B

April 24, 2008
Gilead Sciences to Present at the Morgan Stanley Global Healthcare Unplugged Conference on Wednesday, April 30

April 24, 2008
Gilead Announces 72-Week Data From Two Pivotal Phase III Studies Evaluating Viread(R) for the Treatment of Chronic Hepatitis B

April 21, 2008
Robin L. Washington to Join Gilead as Senior Vice President and Chief Financial Officer

April 16, 2008
Gilead Sciences Announces First Quarter 2008 Financial Results

April 9, 2008
Gilead Sciences to Release First Quarter 2008 Financial Results on Wednesday, April 16, 2008

March 19, 2008
European CHMP Issues Positive Opinion for Viread(R) for the Treatment of Chronic Hepatitis B

March 10, 2008
Gilead Sciences to Present at Two Upcoming Investor Conferences

March 7, 2008
Gilead Sciences Submits Marketing Authorisation Application for Aztreonam Lysine 75 mg Powder for Nebuliser Solution, a Potential New Treatment for Cystic Fibrosis, to European Medicines Agency

March 6, 2008
Gilead Appoints Dr. John J. Toole as Senior Vice President, Corporate Development

February 29, 2008
Gilead Announces $500 Million Accelerated Share Repurchase

January 30, 2008
Gilead Sciences to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on Tuesday, February 5

January 23, 2008
Gilead Sciences Announces Fourth Quarter and Full Year 2007 Financial Results

January 21, 2008
Gilead Announces Departure of Caroline Dorsa

January 16, 2008
Gilead Sciences to Release Fourth Quarter and Year End 2007 Financial Results on Wednesday, January 23, 2008

January 3, 2008
Gilead Sciences to Present at the 26th Annual JPMorgan Healthcare Conference on Monday, January 7